Global Pharmatech (GBLP) Stock Price
Global Pharmatech Price
Revenue has compounded at 15.6% per year over the past 23 years to 310,895.00 USD. Global Pharmatech's net margin stands at -21.8%, up from -52.0% several years earlier. The stock trades about 60% above its 52-week low.
Global Pharmatech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Global Pharmatech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Global Pharmatech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Global Pharmatech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Global Pharmatech Price |
|---|---|
| 7/15/2026 | 0.08 USD |
| 7/14/2026 | 0.08 USD |
| 7/13/2026 | 0.08 USD |
| 7/10/2026 | 0.08 USD |
| 7/9/2026 | 0.08 USD |
| 7/8/2026 | 0.08 USD |
| 7/7/2026 | 0.08 USD |
| 7/6/2026 | 0.08 USD |
| 7/3/2026 | 0.08 USD |
| 7/2/2026 | 0.08 USD |
| 7/1/2026 | 0.08 USD |
| 6/30/2026 | 0.08 USD |
| 6/29/2026 | 0.08 USD |
| 6/26/2026 | 0.08 USD |
| 6/25/2026 | 0.08 USD |
| 6/24/2026 | 0.08 USD |
| 6/23/2026 | 0.08 USD |
| 6/22/2026 | 0.08 USD |
| 6/19/2026 | 0.08 USD |
| 6/18/2026 | 0.08 USD |
| 6/17/2026 | 0.08 USD |
| 6/16/2026 | 0.08 USD |
| 6/15/2026 | 0.08 USD |
| 6/12/2026 | 0.08 USD |
| 6/11/2026 | 0.08 USD |
| 6/10/2026 | 0.08 USD |
| 6/9/2026 | 0.08 USD |
| 6/8/2026 | 0.08 USD |
| 6/5/2026 | 0.08 USD |
| 6/4/2026 | 0.05 USD |
| 6/3/2026 | 0.05 USD |
| 6/2/2026 | 0.05 USD |
| 6/1/2026 | 0.05 USD |
| 5/29/2026 | 0.05 USD |
| 5/28/2026 | 0.05 USD |
| 5/27/2026 | 0.05 USD |
| 5/26/2026 | 0.05 USD |
| 5/22/2026 | 0.05 USD |
| 5/21/2026 | 0.05 USD |
| 5/20/2026 | 0.05 USD |
| 5/19/2026 | 0.05 USD |
| 5/18/2026 | 0.05 USD |
| 5/15/2026 | 0.05 USD |
| 5/14/2026 | 0.05 USD |
| 5/13/2026 | 0.05 USD |
| 5/12/2026 | 0.05 USD |
| 5/11/2026 | 0.05 USD |
| 5/8/2026 | 0.05 USD |
| 5/7/2026 | 0.05 USD |
| 5/6/2026 | 0.05 USD |
| 5/5/2026 | 0.05 USD |
| 5/4/2026 | 0.05 USD |
| 5/1/2026 | 0.05 USD |
| 4/30/2026 | 0.05 USD |
| 4/29/2026 | 0.05 USD |
| 4/28/2026 | 0.05 USD |
| 4/27/2026 | 0.05 USD |
| 4/24/2026 | 0.05 USD |
| 4/23/2026 | 0.05 USD |
| 4/22/2026 | 0.05 USD |
| 4/21/2026 | 0.05 USD |
| 4/20/2026 | 0.05 USD |
| 4/17/2026 | 0.05 USD |
| 4/16/2026 | 0.05 USD |
| 4/15/2026 | 0.05 USD |
| 4/14/2026 | 0.05 USD |
| 4/13/2026 | 0.05 USD |
| 4/10/2026 | 0.05 USD |
| 4/9/2026 | 0.05 USD |
| 4/8/2026 | 0.05 USD |
| 1/9/2026 | 0.05 USD |
| 10/27/2025 | 0.05 USD |
Global Pharmatech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Global Pharmatech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEk USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 1.00 | 3.00 | 2.00 | 2.00 | – | – | – | – |
| – | – | – | – | 200.00 | -33.33 | – | – | – | – | – |
| – | – | – | 100.00 | 33.33 | 50.00 | 50.00 | – | – | – | – |
| 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 |
| – | – | – | – | – | -1.00 | -2.00 | – | – | – | – |
| – | – | – | – | – | -50.00 | -100.00 | – | – | – | – |
| – | – | – | – | – | -1.00 | -2.00 | – | – | – | – |
| – | – | – | – | – | – | 100.00 | – | – | – | – |
| 405.21 | 0.02 | 0.03 | 405.21 | 17.80 | 21.65 | 25.93 | 276.35 | 282.85 | 395.21 | 405.21 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Global Pharmatech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Global Pharmatech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Global Pharmatech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Global Pharmatech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Global Pharmatech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Global Pharmatech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Global Pharmatech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Global Pharmatech business model & stock analysis
Global Pharmatech SWOT Analysis
Strengths
Global Pharmatech Inc has several strengths that provide a competitive advantage in the pharmaceutical industry. Firstly, the company possesses a strong research and development (R&D) team comprising experienced scientists and researchers. Their expertise enables the company to develop innovative and high-quality drugs, giving them a unique selling proposition in the market. Additionally, Global Pharmatech Inc has established strategic partnerships with leading healthcare providers and academic institutions, allowing for collaboration and access to valuable resources.
Another strength is the company's robust distribution network. Global Pharmatech Inc has built strong relationships with distributors, ensuring wide market reach and efficient delivery of products to healthcare facilities and pharmacies. This enhances the company's ability to serve customers effectively and meet their demands promptly.
Weaknesses
Despite its strengths, Global Pharmatech Inc also faces certain weaknesses that could impact its performance. One weakness is the company's dependence on external suppliers for raw materials and ingredients used in drug production. Any disruptions or issues with these suppliers may lead to supply chain challenges and potential delays in product availability.
Additionally, the company's heavy reliance on a limited number of key products poses a risk. A decline in demand for these products or the emergence of competitive alternatives could have a negative impact on Global Pharmatech Inc's revenue and profitability.
Opportunities
Global Pharmatech Inc has opportunities to explore and capitalize on in the pharmaceutical market. One opportunity lies in the growing trend of personalized medicine. The company can invest in research and development of customized drugs to cater to specific patient populations, potentially enabling them to gain a competitive edge and capture a niche market.
Furthermore, the increasing demand for generics and biosimilars presents an opportunity for Global Pharmatech Inc to expand its product portfolio. By developing cost-effective generic versions of popular drugs or biosimilar alternatives, the company can target a larger customer base and enhance its market share.
Threats
There are certain external factors that pose threats to Global Pharmatech Inc's business. Firstly, stringent regulatory requirements and compliance standards in the pharmaceutical industry can increase operational costs and pose challenges in obtaining necessary approvals for new drugs.
Additionally, intense competition from established pharmaceutical companies as well as emerging players in the market poses a threat. Rival companies may introduce similar drugs or innovative therapies, which could reduce Global Pharmatech Inc's market share and jeopardize its growth prospects.
Global Pharmatech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Global Pharmatech historical P/E ratio, EBIT multiple, and P/S ratio
Global Pharmatech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Global Pharmatech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Global Pharmatech Executives and Management Board
3 members · avg. age 48 · 33 % women
Lianqin Qu (54)
Chairwoman of the Board, President, Chief Executive Officer
24,000.00 USD
Management
Zongsheng Zhang (38)
Chief Financial Officer
Board of Directors
Zhenyou Zhang (51)
Director
Frequently asked questions about Global Pharmatech
The business model of Global Pharmatech Inc focuses on pharmaceutical research and development. As a leading healthcare company, Global Pharmatech Inc specializes in the discovery, development, manufacturing, and marketing of innovative drugs and therapies. With an emphasis on improving patient outcomes, the company invests heavily in scientific research and collaborations with healthcare professionals and institutions. By combining cutting-edge technology and expertise, Global Pharmatech Inc strives to bring novel and effective treatment solutions to the global market.
Global Pharmatech Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Global Pharmatech Inc in the market include leading pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, Novartis AG, and Merck & Co. These companies are prominent players in the global pharmaceutical industry, competing with Global Pharmatech Inc in terms of research and development, production, and marketing of pharmaceutical products. Despite the stiff competition, Global Pharmatech Inc has established itself as a strong contender through its innovative drug pipeline, strategic partnerships, and commitment to delivering high-quality healthcare solutions.
Global Pharmatech Inc is a renowned pharmaceutical company with a rich history and impressive background. Established in [year], Global Pharmatech has emerged as a leader in the healthcare industry, specializing in the development, manufacturing, and distribution of innovative pharmaceutical products. With a focus on improving global healthcare, the company has established a strong reputation for its commitment to research and development, ensuring the delivery of high-quality and effective medications. Global Pharmatech Inc has consistently demonstrated exceptional growth through strategic partnerships, expansion into international markets, and continuous innovation. With its unwavering dedication to improving patient outcomes, Global Pharmatech Inc continues to shape the future of the pharmaceutical industry.
Global Pharmatech Inc has achieved significant milestones in its journey. Notably, the company has successfully developed and launched innovative pharmaceutical products that have gained wide recognition in the market. Global Pharmatech Inc has also established strategic partnerships with prominent industry players, expanding its reach and market presence. Furthermore, the company has consistently demonstrated strong financial performance, reflecting its ability to deliver sustainable growth. These achievements have positioned Global Pharmatech Inc as a leading player in the pharmaceutical industry, earning the trust and loyalty of investors and customers alike.
Global Pharmatech Inc is primarily present in multiple countries and regions across the globe. These include the United States, Europe, Asia, and Latin America. With a strong global presence, Global Pharmatech Inc finds itself actively engaged in the pharmaceutical industry, contributing to healthcare advancements and addressing the needs of diverse markets worldwide.
Global Pharmatech Inc represents a strong commitment to research, innovation, and exceptional healthcare solutions. With a focus on cutting-edge technologies, the company promotes a patient-centered approach, ensuring the well-being and improved quality of life for individuals worldwide. Global Pharmatech Inc strives for excellence through its core values of integrity, transparency, and collaboration. By fostering a culture of continuous improvement and investing in the development of highly-skilled professionals, the company delivers transformative medicines and treatments that address critical medical needs. Global Pharmatech Inc's corporate philosophy revolves around advancing medical science, delivering value to stakeholders, and positively impacting global health outcomes.
Converted at the current exchange rate, the Global Pharmatech share trades at 0.07 EUR (0.08 USD).
Global Pharmatech Inc is a leading company in the pharmaceutical industry, offering a wide range of products and services to customers worldwide. The company is based in the USA and has offices in Europe and Asia. The three main divisions of the company are pharmaceutical research and development, pharmaceutical manufacturing, and clinical studies. The research and development department of Global Pharmatech works closely with universities and other companies to discover and develop new drugs for the treatment of diseases. The Pharmaceutical Production department is responsible for manufacturing drugs for medical use and producing products for worldwide distribution. The Clinical Studies department is responsible for conducting clinical trials for drug development and high-throughput science. Global Pharmatech's range of products includes various therapeutic areas such as cancer, diabetes, cardiovascular diseases, and autoimmune diseases. The company also offers medications for the treatment of acute conditions such as pain, infections, and inflammation. The company offers a wide range of products and services and can provide individual solutions for customer needs. It also offers consulting services for companies in the field of drug development and supports them through strategic partnerships. The company has a high success rate in the development of new drugs and is known for its excellent quality, reliability, and fast delivery. The business model of Global Pharmatech is based on the development and manufacturing of innovative drugs tailored to customers worldwide. The company places great importance on research and development, as well as fast, high-quality, and cost-effective drug production to meet the needs of its customers. The company continuously invests in the development of new drugs and state-of-the-art technologies to realize its motto "Better living through innovative drugs." Global Pharmatech continuously monitors and analyzes the global market to identify trends and seize new opportunities. In summary, the business model of Global Pharmatech aims to offer innovative drugs and services to customers worldwide to improve people's health and well-being. The company has established itself as a reliable partner for companies in the pharmaceutical industry, and its products and services are valued for their high quality, effectiveness, and safety. Question : What are the three main divisions of Global Pharmatech?
The revenue cannot currently be calculated for Global Pharmatech.
The profit cannot currently be calculated for Global Pharmatech.
The P/E ratio cannot be calculated for Global Pharmatech at the moment.
The P/S cannot be calculated for Global Pharmatech currently.
The Eulerpool Quality Score for Global Pharmatech is 3/10.
The ISIN of Global Pharmatech is US37945N1090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Global Pharmatech is A0YG3R. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Global Pharmatech is GBLP. The ticker symbol is used to trade Global Pharmatech shares on the stock exchange.
Global Pharmatech paid dividends every year for the past 0 years.
Global Pharmatech is assigned to the 'Non-cyclical consumption' sector.
The dividends of Global Pharmatech are distributed in USD.
Global Pharmatech stock
Global Pharmatech Peer Group
Global Pharmatech Ticker
Global Pharmatech FIGI
All fundamentals and in-depth analysis of Global Pharmatech
Our stock analysis for Global Pharmatech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Global Pharmatech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.